What Pricing Pressure? Recordati Continues Push Into Turkey With Latest Acquisition
This article was originally published in PharmAsia News
Executive Summary
Although many pharma companies are reducing investments in Turkey after a series of controversial government price cuts, Italian drug maker Recordati S.p.A is doing just the opposite, buying Istanbul-based Dr. F. Frick Ilac for $130 million earlier this month, its second acquisition in Turkey in three years. Recordati, in fact, sees significant growth opportunities in Turkey and Eastern European, and says more deals could be on the way